Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

GenMark Diagnostics

- PMLiVE

Roche engaged in talks with FDA for Alzheimer’s drug candidate

CEO Severin Schwan told reporters Roche will complete a phase 3 trial of gantenerumab in the second half of 2022

- PMLiVE

BioNTech plans acquisition of Kite’s TCR cell therapy R&D platform

German biotech company said the acquisition will boost its presence in the US

- PMLiVE

British officials reportedly monitoring Philip Morris’ proposed acquisition of Vectura

PMI, which owns a portfolio of tobacco products, announced a deal to acquire Vectura for £927m earlier this week

- PMLiVE

Philip Morris International to acquire inhaled drug company Vectura for $1.2bn

Vectura is developing inhaled drug delivery solutions for a number of diseases including COVID-19

- PMLiVE

AstraZeneca clears latest hurdle for Alexion acquisition after EU clearance

AZ first announced the proposed acquisition of Alexion in December 2020

- PMLiVE

Roche’s gantenerumab improves biomarkers in inherited form of Alzheimer’s disease

However, anti-amyloid antibody did not show evidence of cognitive benefit for patients

- PMLiVE

Regeneron’s COVID-19 drug boosts survival in hospitalised patients lacking antibodies

REGEN-COV reduced the risk of death among patients who did not have a natural antibody response

Roche Basel Switzerland

Roche reveals four-year follow-up data for Venclyxto in CLL at EHA2021

At 30 months post-treatment, 26.9% of Venclyxto-treated patients had undetectable minimal residual disease

- PMLiVE

Nordic Capital acquires ADVANZ PHARMA for $846m

ADVANZ PHARMA shareholders to receive $17.26 per share under the terms of the deal

- PMLiVE

MorphoSys expands oncology pipeline with $1.7bn acquisition of Constellation Pharmaceuticals

MorphoSys has also entered into a long-term strategic funding partnership with Royalty Pharma

Roche Basel Switzerland

EC approves Venclyxto-based combinations for newly diagnosed AML

The treatment is approved for newly diagnosed acute myeloid leukaemia patients who can’t receive intensive chemotherapy

- PMLiVE

UK’s Competition and Markets Authority to review AZ/Alexion merger

Proposed acquisition has already received competitions clearance in the US and Canada

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links